Broadwood Partners, L.P. and its affiliates announced that Glass, Lewis & Co., LLC, an independent proxy advisory firm, has recommended that the shareholders of STAAR Surgical Company (STAA) vote “AGAINST” the proposed acquisition of STAAR by Alcon Inc. (ALC) on the terms announced on August 5, 2025. “Glass Lewis’s recommendation and findings underscore our strong belief that STAAR conducted a highly questionable sale process that resulted in an ill-timed deal that significantly undervalues the Company and its compelling prospects. We are confident that better alternatives exist than this deeply flawed and short-sighted transaction,” said Neal C. Bradsher, Broadwood Founder and President.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on STAA:
- Defender Capital says opposes Staar Surgical’s proposed sale to Alcon
- Yunqi Capital urges STAAR shareholders to oppose Alcon merger
- Staar Surgical issues statement in response to claims made by Broadwood Partners
- Broadwood Partners urges Staar Surgical holders to vote against Alcon merger
- Alcon, Staar Surgical announce expiration of HSR waiting period